Search research articles
Contact Us
Filters
Showing results (151-160 of 175) with videos related to
Page
of 18
Sort By:
Hepatology International
|
February 28, 2025
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
Shigeo Shimose, Issei Saeki, Takanori Ito, et al.
Journal of Clinical Medicine
|
March 25, 2022
Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, et al.
Journal of Gastroenterology
|
July 1, 2025
Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, et al.
Annals of Clinical Biochemistry
|
July 13, 2022
Comparison of two primer-probe sets of <i>Fusobacterium nucleatum</i> using droplet digital polymerase chain reaction for the detection of colorectal neoplasia from faecal samples
Yuko Yamaoka, Mai Sasai, Yutaka Suehiro, et al.
Journal of Gastroenterology and Hepatology
|
November 14, 2025
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
Takanori Ito, Shigeo Shimose, Issei Saeki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
February 24, 2023
Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Yurika Yamauchi, Issei Saeki, Takahiro Yamasaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Nationwide survey of patients with acute liver failure and late-onset hepatic failure in Japan seen between 2016 and 2021
Nobuaki Nakayama, Masamitsu Nakao, Yoshihito Uchida, et al.
Journal of Gastroenterology
|
April 11, 2012
Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy
Shuji Terai, Haruko Tanimoto, Masaki Maeda, et al.
Tissue Engineering. Part B, Reviews
|
January 24, 2014
Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells
Shuji Terai, Taro Takami, Naoki Yamamoto, et al.
Gastro Hep Advances
|
August 12, 2024
Distinction of Drug-Induced Liver Injury From Autoimmune Hepatitis in Patients With Acute Liver Injury: Proposal of a Combination of Diagnostic Scores
Keisuke Kakisaka, Nobuaki Nakayama, Kotaro Kumagai, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 175) with videos related to
Sort By:
Page
of 18
Hepatology International
|
February 28, 2025
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
Shigeo Shimose, Issei Saeki, Takanori Ito, et al.
Journal of Clinical Medicine
|
March 25, 2022
Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, et al.
Journal of Gastroenterology
|
July 1, 2025
Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, et al.
Annals of Clinical Biochemistry
|
July 13, 2022
Comparison of two primer-probe sets of <i>Fusobacterium nucleatum</i> using droplet digital polymerase chain reaction for the detection of colorectal neoplasia from faecal samples
Yuko Yamaoka, Mai Sasai, Yutaka Suehiro, et al.
Journal of Gastroenterology and Hepatology
|
November 14, 2025
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
Takanori Ito, Shigeo Shimose, Issei Saeki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
February 24, 2023
Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Yurika Yamauchi, Issei Saeki, Takahiro Yamasaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Nationwide survey of patients with acute liver failure and late-onset hepatic failure in Japan seen between 2016 and 2021
Nobuaki Nakayama, Masamitsu Nakao, Yoshihito Uchida, et al.
Journal of Gastroenterology
|
April 11, 2012
Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy
Shuji Terai, Haruko Tanimoto, Masaki Maeda, et al.
Tissue Engineering. Part B, Reviews
|
January 24, 2014
Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells
Shuji Terai, Taro Takami, Naoki Yamamoto, et al.
Gastro Hep Advances
|
August 12, 2024
Distinction of Drug-Induced Liver Injury From Autoimmune Hepatitis in Patients With Acute Liver Injury: Proposal of a Combination of Diagnostic Scores
Keisuke Kakisaka, Nobuaki Nakayama, Kotaro Kumagai, et al.
Page
of 18